STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1/2-4; 3/39-45	Title; Abstract/Method
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3/50-65; 4/66-70	Abstract/ Results;
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	4/73-121	Introduction
Objectives	3	State specific objectives, including any prespecified hypotheses	6/122-124	Introduction
Methods				
Study design	4	Present key elements of study design early in the paper	7/127-129	Methods/Patients
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7/127-131	Methods/Patients
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	7-8/137-143 9/168-169	Methods/Patients Methods/Assessment
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	8/145-159	Methods/Patients
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8/159-164	Methods/Assessment
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7/129-130 7-8/165-175	Methods/Patients Methods/Assessment
Bias	9	Describe any efforts to address potential sources of bias	7-8/145-149	Methods/Patients
Study size	10	Explain how the study size was arrived at	7/130-131	Methods/Patients
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9/177-178 9/181-183	Methods/Statistical analysis

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10/177-190	Methods/Statistical
		(b) Describe any methods used to examine subgroups and interactions	8/150-155	Methods/Patients
		(c) Explain how missing data were addressed	9/178-179	Methods/Statistical
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	-	-
		(e) Describe any sensitivity analyses	-	-
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10/193-195	Results/Clinical-pathological features
		(b) Give reasons for non-participation at each stage	-	-
		(c) Consider use of a flow diagram	-	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10-11/196-218	Results/Clinical-pathological features; Table 1
		(b) Indicate number of participants with missing data for each variable of interest	10-11/198-215	Results/Clinical-pathologi
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	12/227-228	Results/Effectiveness: PFS
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	12/246-247	Results/Effectiveness: PFS
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	-	-
		Cross-sectional study—Report numbers of outcome events or summary measures	-	-
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	-	-
		(b) Report category boundaries when continuous variables were categorized	12/241-243	Results/Effectiveness: PFS
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12-14/246-271	Results/Antitumor
Discussion				
Key results	18	Summarise key results with reference to study objectives	14/273-281	Discussion
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	17/334-346	Discussion

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15-16/293-327	Discussion
Generalisability	21	Discuss the generalisability (external validity) of the study results	14/282-288	Discussion
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	-	-

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/tau-22-312
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copy editing and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.